Welcome to our dedicated page for KYNTRA BIO news (Ticker: KYNB), a resource for investors and traders seeking the latest updates and insights on KYNTRA BIO stock.
Kyntra Bio reports news around its oncology and rare disease development programs, financial results, and public-company updates. Recurring items include clinical updates for FG-3246 in metastatic castration-resistant prostate cancer, roxadustat development for anemia associated with lower-risk myelodysplastic syndromes, and work involving the FG-3180 CD46-targeted PET biomarker.
Company announcements also cover quarterly and annual results, business updates, medical and investor conference presentations, and corporate matters related to its Nasdaq-listed common stock and former FibroGen identity.
Kyntra Bio (Nasdaq: KYNB) reported first quarter 2026 results and pipeline progress. Revenue from continuing operations was $3.7 million versus $2.7 million a year ago; net loss was $15.1 million (‑$3.74 per share) versus $16.8 million (‑$4.15).
The Phase 2 FG-3246 mCRPC trial is enrolling with interim analysis expected in 4Q 2026. Positive FG-3246 combination data with enzalutamide and biomarker insights from FG-3180 were presented. A pivotal Phase 3 trial of roxadustat in LR‑MDS is being finalized, targeting initiation in 2H 2026. Kyntra reported $100.3 million in cash and equivalents, guiding runway into 2028.
Kyntra Bio (Nasdaq: KYNB) will report first quarter 2026 financial results on Monday, May 11, 2026 after market close and host a conference call and webcast at 5:00 PM ET.
The management team will present corporate and financial updates, followed by a live Q&A; a replay will be available for a limited time on the company’s Events & Presentations page.
Kyntra Bio (Nasdaq: KYNB) will present at the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026. CEO Thane Wettig will deliver the company presentation on April 13, 2026 at 1:30 PM EDT. A live webcast and a 90-day replay will be available on the company website.
Management will be available for one-on-one meetings via Needham representative requests.
Kyntra Bio (NASDAQ: KYNB) reported Q4 and full‑year 2025 results and clinical updates on March 16, 2026. Key clinical highlights include an actively enrolling Phase 2 FG‑3246 monotherapy trial in mCRPC with interim analysis expected in 2H 2026, investigator‑sponsored combo data showing median rPFS of 7.0 months (10.1 months in a subgroup), and submission of a pivotal Phase 3 protocol for roxadustat in LR‑MDS. Financials: Q4 2025 revenue $1.3M, FY2025 revenue $6.4M, FY2025 net loss $58.2M, and $109.4M in cash, cash equivalents, investments, and accounts receivable providing runway into 2028.
Kyntra Bio (Nasdaq: KYNB) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close. Management will host a conference call and webcast the same day at 5:00 PM ET to discuss results and provide a business update.
A live Q&A follows the presentation. A replay of the webcast will be available for a limited time on Kyntra Bio’s Events & Presentations page. Phone access requires registration to receive dial-in details.
Kyntra Bio (NASDAQ: KYNB) reported positive investigator‑sponsored Phase 1b/2 data for FG-3246 plus enzalutamide in mCRPC. In 44 biomarker‑unselected patients the combination produced a composite response rate 21% overall and 40% in patients with only one prior ARPI; median rPFS was 7.0 months overall and 10.1 months for one‑prior ARPI patients. The MTD/recommended dose was 2.1 mg/kg FG-3246 with 160 mg/day enzalutamide. Higher FG-3180 PET uptake trended with PSA50 response (p=0.053). Phase 2 monotherapy interim analysis expected in 2H 2026.
Kyntra Bio (Nasdaq: KYNB) announced management will participate in investor conferences in February–March 2026. Presentations: Oppenheimer 36th Annual Healthcare Life Sciences (virtual, Feb 26, 2026, 2:40–3:10 PM ET) and Leerink Global Healthcare Conference (Miami, Mar 11, 2026, 2:20–2:50 PM ET).
Management will be available for one-on-one meetings; webcasts are provided and presentation replays will be posted on the company's Events & Presentations investor page for 90 days.